CCL2 and osteoarthritis: In osteoarthritis, BROM reduces symptoms by inhibiting the expression of pro-inflammatory cytokines, including interleukin-1β (IL-1β), IL-6, monocyte chemoattractant protein-1 (MCP-1), and TNF-α, which contribute to inflammation, cartilage degradation, and joint tissue damage [165,166,167].